- Home
- BDTX vs CURI Comparison
BDTX vs CURI Comparison
Compare BDTX & CURI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | CURI |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 154.7M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BDTX | CURI |
|---|---|---|
| Price | $2.21 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.67 | $5.83 |
| AVG Volume (30 Days) | 637.5K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.36% |
| EPS Growth | ★ 130.71 | 54.17 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $78,043,000.00 |
| Revenue This Year | N/A | $14.91 |
| Revenue Next Year | N/A | $12.91 |
| P/E Ratio | ★ N/A | $24.50 |
| Revenue Growth | N/A | ★ 9.52 |
| 52 Week Low | $1.60 | $2.30 |
| 52 Week High | $4.94 | $5.51 |
Technical Indicators
Market Signals| Indicator | BDTX | CURI |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 50.00 |
| Support Level | $2.13 | $2.32 |
| Resistance Level | $2.26 | $2.95 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 89.52 | 17.22 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.